CT
Cytek Biosciences, Inc.
CTKB · NASDAQ
$5.68 -0.87% (-$0.05)
1M +24.02%
Market Cap $733.5M
P/E Ratio -
Div. Yield -
ROE 23.53%
Bulios Fair Price
$3.18
44.0% downside
Current Price
$5.68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CTKB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
66 /100
Fair P/S 3.55x
P/B 2.28x
P/E N/A
Growth
43 /100
Stable Rev. growth 7.10%
Book val. growth 7.03%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 53.23%
Net margin 38.98%
Op. margin 21.60%
Quality
6 /100
Poor ROIC 23.49%
ROE 23.53%
ROA 18.03%
Debt
69 /100
Low Debt/Equity 0.08x
Current ratio 4.48x
Int. coverage -22.16x
Stability
45 /100
Moderate Beta 1.19x
Rev. volatility 9.09%
EPS volatility 541.00%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CTKB
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Wenbin Jiang
Employees
682
Headquarters
Fremont
Upcoming events
04 NOV
Earnings
Upcoming earnings report